已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

POS0054 AN OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY TO EVALUATE RELMACABTAGENE AUTOLEUCEL, THE CD-19 DIRECTED CAR-T CELL THERAPY, FOR ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS IN CHINA

打开标签 医学 内科学 临床试验
作者
Yanmei Hu,Mary Y. Heng,Weiguo Xie,C. Mei,Dazhou Liao,Jun Shu,Zhiqiang Chen,Menggen Ma,Zhifeng Zhou,Wei Huang
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:83: 328-329 被引量:6
标识
DOI:10.1136/annrheumdis-2024-eular.3246
摘要

Background:

B-cell mediated autoimmune disease, such as systemic lupus erythematosus (SLE), can cause widespread inflammation and organ damages, and even life-threatening symptoms for some severe patients. Despite tremendous progress in the clinical management of SLE, many patients do not respond to the currently used treatments. Autoreactive B cells play a key role in the pathogenesis of autoimmune diseases like SLE. Recently, clinical cases suggested that CAR-T therapies showed potential to promote full clinical remission in SLE.

Objectives:

To evaluate the safety and efficacy of relma-cel in patients with active SLE.

Methods:

An open-label, single arm, multicenter study (NCT05765006) to evaluate the safety, efficacy, and cellular kinetics of relma-cel in patients with active SLE in China is currently ongoing. Following the lymphodepleting therapy of cyclophosphamide 250 mg/m2/day and fludarabine 25 mg/m2/day, patients were to be dosed with 25 or 50 or 75x10^6 CAR+ T cells. For efficacy, we assessed the changes of autoantibodies, complement components (C3), SELENA-SLEDAI scores and proteinuria from baseline. We also analyzed the composite endpoint of response rates assessed by SRI-4 and LLDAS. For safety, we reported any level of adverse event (AEs) and serious adverse events (SAEs), including the CRS (cytokine release syndrome) and neurotoxicity (NT). We monitored CAR-T cell kinetics by quantitative polymerase chain reaction (PCR) and flow cytometry.

Results:

As of 18 Dec 2023, three patients received 25x10^6 CAR+ T cells and were followed for at least 4 months. All patients were female, aged between 21 and 36 years. Two had a medical history of more than 10 years, and one had 1 year. All patients had multiorgan involvement, including 3 skin, 2 kidney, 2 hematology and 1 joint. All patients had active SLE at baseline, with SELENA-LEDAI between 8 and 14. Despite their young age, all patients previously exposed to high dose steroids and several immunosuppressive drugs (3 hydroxychloroquine [HCQ], 2 mycophenolate mofetil [MMF], 2 tacrolimus, 1 methotrexate [MTX]), and two patients received biological agents (2 telitacicept, 1 beliuzumab). Two patients received bridging therapies (1 corticosteroid and tacrolimus 1 corticosteroid, MMF and HCQ). After relma-cel infusion, Disease activity assessed by SELENA-SLEDAI decreased to 0 or 1. SRI-4 achieved in all patients. LLDAS achieved in two patients. Signs and symptoms of SLE continuously improved in all patients. Autoantibodies level of all patients declined, accompanied with elevated level of C3; only one patient's anti-dsDNA level initially decreased but then increased from D120. Elevated proteinuria at baseline in two patients, and decreased to normal range after infusion. As of the data cut-off, all patients stayed drug-free, meaning not received any anti-SLE treatment after relma-cel infusion. Detailed data are shown in Figure 1. CRS occurred in two patients (one of grade 1 and one of grade 3). No NT reported. Cytopenia occurred in two patients. Infection, MAS and effusion were observed in one single patient. With steroid, anti-infection, and supportive treatment, the patient completely recovered around Day60. As of the data cut-off, all AEs occurred were resolved. PK data showed cellular expansion with a median peak concentration (Cmax) of 19.72 cells/μL by flow cytometry and Tmax between 8-22 days post infusion. Complete B cell depletion were observed (shown as 0.01 cells/μL). The nadir of B concertation was observed from Day8-11 and then starting recovery at Day60. Majority (> 97%) of the recovered B cells were naïve B cells, consistent with pervious reports.

Conclusion:

Previously known adverse events to be related to CD19-directed CAR-T cell therapy were observed as expected. Even with the lowest dose level of 25x10^6 CAR+ T cells, preliminary data from the first three patients suggested favorable profiles on safety, CAR-T cell expansion and B cell depletion, indicated promising efficacy of relma-cel in active SLE. Patients will be followed up further and more patients will be dosed with higher doses to observe long term safety and efficacy as well as to determine the potential target treatment dose.

REFERENCES:

NIL.

Acknowledgements:

NIL.

Disclosure of Interests:

Yu Hu: None declared, Mei Heng: None declared, Wei Xie: None declared, Chunli Mei: None declared, Danying Liao: None declared, Jinhui Shu: None declared, Zhaozhao Chen: None declared, Meilin Ma JW Therapeutics (Shanghai) Co. Ltd., Zisong Zhou JW Therapeutics (Shanghai) Co. Ltd., Weici Huang JW Therapeutics (Shanghai) Co. Ltd.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小Y完成签到,获得积分10
刚刚
所所的应助被漂亮的保温杯采纳,获得10
1秒前
lucy发布了新的文献求助10
2秒前
王皮皮完成签到,获得积分20
2秒前
2秒前
sandeyuntao发布了新的文献求助10
3秒前
edisonzz发布了新的文献求助10
3秒前
顾矜的应助被77采纳,获得10
4秒前
Clarissa发布了新的文献求助10
4秒前
5秒前
Maestro_S的应助被jacksen采纳,获得10
7秒前
充电宝的应助被风吹麦浪采纳,获得10
7秒前
桐桐的应助被风吹麦浪采纳,获得10
7秒前
Tulip发布了新的文献求助10
8秒前
星辰大海的应助被Arvin采纳,获得10
8秒前
haui完成签到,获得积分10
8秒前
jyy发布了新的文献求助10
10秒前
科研通AI6.2的应助被j736999565采纳,获得10
11秒前
阿王完成签到,获得积分10
12秒前
外向思松完成签到,获得积分10
13秒前
Birk发布了新的文献求助10
13秒前
泡芙完成签到 ,获得积分10
13秒前
14秒前
zdk完成签到 ,获得积分20
15秒前
15秒前
包容耳机发布了新的文献求助30
16秒前
Orange的应助被DARKNESS采纳,获得10
16秒前
酷波er的应助被难过的谷芹采纳,获得10
16秒前
16秒前
你不好你不好完成签到 ,获得积分10
17秒前
17秒前
vivian发布了新的文献求助10
21秒前
21秒前
星辰大海的应助被学医自救采纳,获得10
22秒前
James完成签到,获得积分10
24秒前
科研通AI6.3的应助被嘻哈师徒采纳,获得30
24秒前
24秒前
朝阳夕赏完成签到,获得积分10
25秒前
26秒前
顺利的蛋挞完成签到,获得积分10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179129
求助须知:如何正确求助?哪些是违规求助? 9569710
关于积分的说明 21806324
捐赠科研通 7774507
什么是DOI,文献DOI怎么找? 3433008
关于科研通互助平台的介绍 2556912
邀请新用户注册赠送积分活动 2478649